| Management target | Revenue 32.5% FY28 |
|---|
| Revenue growth | 31.2% YoY growth in Q1 FY27. |
|---|---|
| Margins | EBITDA impacted by leadership hires and remediation costs; mid-teens target post-EU. |
| Order book | Received first product order from Australia. |
| Demand visibility | Strong export resilience; expectations for EU market supplies by Q4. |
| Management confidence | High, pending EU-GMP certification finalization. |
Growth
Revenue reached INR 942 million (+31.2% YoY). EBITDA stood at INR 34 million with 3.7% margin; PAT was a loss of INR 40 million.
Outlook
Management guides 30-35% revenue growth for FY28 post-EU-GMP; FY27 growth expected at 10-15% without EU. Capex of INR 15-20Cr planned.
Risks
Primary risk remains the timeline for EU-GMP certification; Middle East geopolitical disruptions showed some initial impact.
Last quarter's promises, checked
Delivered
- Guided EU-GMP inspection in May 2026 → delivered May 4-7 2026 (= BEAT)
- Guided NIP/OTF revenue recovery in Q4 → delivered INR 254M (+sequential recovery) (= BEAT)
- Guided senior leadership expansion → delivered 3 VPs & 1 President hired (= BEAT)
Partly delivered
- Guided EU-GMP reinstatement process → delivered inspection complete, awaiting final report (= PARTIAL)
Missed
- Guided FY26 Revenue broadly in line with FY25 → delivered INR 3,744M (impacted by INR 200-250M MENA loss) (= MISS)
Investor Presentation filed with BSE, NSE: ZIMLAB. Summary written with AI assistance from the document.
Zim Laboratories Ltd: key numbers
- Share price
- ₹138.48
- Market cap
- ₹743.1 Cr
- Revenue (annual)
- ₹374.4 Cr
- Net profit (annual)
- ₹5.84 Cr
- P/E (TTM)
- 201.0×Sector 50.4×
- Promoter holding
- 30.36%+0.01% QoQ
- FII holding
- 0.03%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Zim Laboratories Ltd
All →Zim Laboratories Merger & Restructuring Worth ₹1,404,640 Cr
ZIM Laboratories completed incorporation of its wholly-owned Chilean subsidiary, ZIM Laboratories SpA. The LATAM expansion entity is now operational, marking completion of the February 2026 board-approved plan.
- Value
- ₹14,04,640 Cr
Zim Laboratories Merger & Restructuring
ZIM Laboratories Limited incorporated a wholly owned subsidiary, 'ZIM Laboratories SpA', in Chile. This expansion aims to develop its pharmaceutical business in the LATAM region.
Zim Laboratories Acquisition Worth ₹1.56 Cr
ZIM WOS completed a ₹1.56 Crore investment in stepdown ZIM Scientific Office L.L.C., Dubai, fulfilling the board-approved capital plan. The transaction closes the acquisition announced in August 2025.
- Value
- ₹1.56 Cr
Zim Laboratories Merger & Restructuring Worth ₹2.38 Cr
Zim Laboratories confirmed that its subsidiary, ZIM FZE, completed the previously announced AED 9,16,000 investment in its step-down subsidiary, ZIM Scientific Office LLC.
- Value
- ₹2.38 Cr
Zim Laboratories Investor Presentation: Key Takeaways
Q1 FY27 Total Operating Income rose 31.2% YoY to ₹942 Mn. However, EBITDA fell 40% to ₹34 Mn due to utility/employee costs.
Zim Laboratories Q1 FY27 Results: Net Loss of ₹4 Cr, Loss Widens
Zim Laboratories Ltd reported revenue from operations of ₹94.2 Cr (+31.2% YoY) and a net loss of ₹4 Cr for Q1 FY27.
- Key figure
- Net loss ₹4 Cr